Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients

References

• MojaLLucenteforteEKwagKHSystemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationCochrane Database Syst Rev20149CD01123025220133
   PubMed Web of Science ®Google Scholar
• SarwarSClearfieldESolimanMKAflibercept for neovascular age-related macular degenerationCochrane Database Syst Rev20162CD01134626857947
   PubMed Web of Science ®Google Scholar
• MitchellPBandelloFSchmidt-ErfurthUThe RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edemaOphthalmology2011118461562521459215
   PubMed Web of Science ®Google Scholar
• NguyenQDShahSMKhwajaAATwo-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) studyOphthalmology2010117112146215120855114
   PubMed Web of Science ®Google Scholar
• BrownDMCampochiaroPABhisitkulRBSustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a Phase III studyOphthalmology201111881594160221684606
   PubMed Web of Science ®Google Scholar
• ClarkWLBoyerDSHeierJSIntravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT StudyOphthalmology2016123233033626522708
   PubMed Web of Science ®Google Scholar
• NarayananRPanchalBDasTA randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1Br J Ophthalmol201599795495925631483
   PubMed Web of Science ®Google Scholar
• FingerRPWiedemannPBlumhagenFPohlKHolzFGTreatment patterns, visual acuity and quality-of-life outcomes of the WAVE study – a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in GermanyActa Ophthalmol201391654054623171290
   PubMed Web of Science ®Google Scholar
• HolzFGTadayoniRBeattySMulti-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degenerationBr J Ophthalmol201599222022625193672
   PubMed Web of Science ®Google Scholar
• EhlkenCWilkeTBauer-SteinhusenUAgostiniHTHasanbasicZMüllerSTreatment of neovascular age-related macular degeneration patients with vascular endothelial growth factor inhibitors in everyday practice: Identification of Health Care Constraints in Germany-The PONS StudyRetina Epub201759
   Google Scholar
• Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesOphthalmology2014121119320124084500
   PubMed Web of Science ®Google Scholar
• BoyerDSNguyenQDBrownDMBasuKEhrlichJSRIDE and RISE Research GroupOutcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the Phase III RIDE and RISE TrialsOphthalmology2015122122504.e12513.e126452713
   PubMed Web of Science ®Google Scholar
• BresslerSBGlassmanARAlmukhtarTFive-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edemaAm J Ophthalmol2016164576826802783
   PubMed Web of Science ®Google Scholar
• WykoffCCLeRTKhuranaRNOutcomes with as-needed aflibercept and macular laser following the Phase III VISTA DME Trial: ENDURANCE 12-month extension studyAm J Ophthalmol2017173566327702624
   PubMed Web of Science ®Google Scholar
• Boulanger-ScemamaEQuerquesGAboutFRanibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life settingJ Fr Ophtalmol201538762062725913443
   PubMed Web of Science ®Google Scholar
• MuellerSAgostiniHEhlkenCBauer-SteinhusenUHasanbasicZWilkeTPatient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experimentOphthalmology2016123487688326778346
   PubMed Web of Science ®Google Scholar
• PauleikhoffDBertramBHolzFGDie Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration – therapeutische Strategien: Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands – November 2014Der Ophthalmologe20151123237245 German25739373
   PubMed Web of Science ®Google Scholar
• ZiemssenFHelbigHLemmenKDStellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands: Therapie der diabetischen Makulopathie (Stand April 2013)Klinische Monatsblätter für Augenheilkunde20132300661462823794430
   PubMedGoogle Scholar
• FoxJThe R commander: a basic statistics graphical user interface to RJSS2005149142
   Google Scholar
• SubhiYSørensenTLNeovascular age-related macular degeneration in the very old (≥90 years): epidemiology, adherence to treatment, and comparison of efficacyJ Ophthalmol20172017719492728660080
   PubMed Web of Science ®Google Scholar
• StoreyPPMurchisonAPPizziLTImpact of physician communication on diabetic eye examination adherence: results from a retrospective cohort analysisRetina2016361202726098386
   PubMed Web of Science ®Google Scholar
• SivaprasadSHykinPChakravarthyULoteryAMcKibbinMNapierJA retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UKClin Ophthalmol201610879626834453
   PubMedGoogle Scholar
• ZiemssenFEterNFauserSRetrospektive Untersuchung der Anti-VEGF-Behandlungsrealität und Wirksamkeit bei Patienten mit neovaskulärer altersabhängiger Makuladegeneration (nAMD) in Deutschland. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany]Ophthalmologe20151123246254 German25668709
   PubMed Web of Science ®Google Scholar